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Introduction: Current guidelines do not mention tacrolimus (TAC)
as a treatment option and no consensus has been reported on the
role of tacrolimus in active LN. Recent clinical trials have reported
positive effects of tacrolimus-based regimens for treatment of lupus
nephritis (LN). In order to translate these trials into clinical prac-
tice, we systematically reviewed all clinical studies published thus
far that investigated TAC regimens in LN patients and performed a
meta-analysis.
Methods:We identiﬁed from various databases every clinical study
investigating TAC regimens in LN. Studies were summarized on the
basis of treatment target (induction or maintenance), concomitant
immunosuppression and quality of the data. A meta-analysis was
performed for the efﬁcacy of TAC regimens as induction treatment.
Results: 239 studies were identiﬁed from which 24 were clinical
studies performed in LN patients: 6 case series, 9 cohort studies, 3
case-control studies (CCS) and 6 randomized controlled trials
(RCTs). Further analysis of the 9 controlled trials showed that 7
studies investigated tacrolimus in combination with steroids and 2
tacrolimus with mycophenolate plus steroids. 4 RCTs investigated
TAC regimens as induction treatment and 2 RCTs as maintenance
treatment. Strikingly, there was no consensus in any of the studies
regarding tacrolimus dosing and target trough levels. Importantly,
all the studies were performed in LN patients of Asian ethnicity. A
meta-analysis of TAC regimens for induction treatment showed a
signiﬁcantly higher complete response (RR 1.18, 95% CI 1.04-1.34,
p ¼ 0.01) and a signiﬁcantly lower no response rate (RR 0.71, 95%
CI 0.56-0.90, p<0.01). With respect to safety, no clear differences
between TAC regimens and conventional treatment were observed.
Conclusions: Current studies on TAC regimens for LN are limited,
heterogeneous and predominant uncontrolled studies in patients of
Asian ethnicity. A signiﬁcant clinical efﬁcacy of TAC regimens as
induction treatment was found. However, this cannot be extrapo-
lated beyond Asian LN patient groups. Clearly, these results
mandate further conﬁrmation in multi-ethnic, randomized trials.
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Introduction: Human renal microvascular endothelial cells (RMEC)
normally express high levels of HLA class II, even when no
inﬂammation is present by histology. Previous work in the lab with
isolated (cultured) RMEC showed that the cells present peptide in a
DR restricted manner to activate antigen-speciﬁc T cells. T cell
proliferation and cytokine secretion were decreased by CD40 and
CD58 antibodies and increased with CD274 (PD-L1) antibodies. We
hypothesized that RMEC express T cell inhibitory molecules in
vivo to prevent or limit T cell activation to HLA class II presented
peptides.
Nivolumab, a programed death 1 (PD1) inhibitor, is a new
immunotherapy option for a growing number of cancer types,
including lung cancer, advanced renal cell carcinoma, and meta-
static melanoma. It selectively binds PD1 to prevent interactionS14with its ligands PD-L1 (CD274, B7H1) and PD-L2 (CD273, B7H2).
PD-1 is expressed on activated T and B lymphocytes and myeloid
cells. Binding to its ligands transmits an inhibitory signal which
reduces the proliferation of these cells. Expression of PD1 ligands
on tumor cells enables them to suppress lymphocyte responses to
tumor antigens. Monoclonal antibodies targeting PD1 removes this
suppression, thereby enhancing T-cell responses to promote anti-
tumor activity.
Methods: Flow cytometry was used to identify RMEC and assess
their expression of PD1 ligands and T cell co-stimulatory proteins.
Medical records and pathology slides were reviewed for patients
who developed acute kidney injury while being treated with
nivolumab.
Results: Flow cytometry studies identiﬁed high levels of PD-L1 on
RMEC from normal human kidneys.
Four patients were identiﬁed who developed acute kidney
injury while receiving PD1 blocking antibody therapy for their
cancers. Three underwent renal biopsy which showed interstitial
nephritis with intense inﬂammation around capillaries. Other cau-
ses of interstitial nephritis were not identiﬁed from clinical history.
Conclusions: Our interpretation of RMEC’s ability to activate T
cells in a class II-peptide dependent manner, their high levels of
inhibitory ligand PD-L1 (CD274) and now the development of
interstitial inﬂammation in some patients receiving anti-PD1
monoclonal therapy is that RMEC are poised to present peptide
from circulating antigen as an immune surveillance system, with
the PD1 pathway functioning to restrain T cell activation. Other
human organs also express high levels of HLA class II on micro-
vascular endothelial cells. Hence our hypothesis of a kidney
capillary endothelium forming an immune surveillance system may
also pertain to other organs.
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Introduction: Chronic kidney disease (CKD) is a major risk factor for
cardiovascular disease (CVD), partly due to endothelial dysfunc-
tion, and chronic inﬂammation. Disturbed function of the immune
system in CKD patients is witnessed through the high levels of
cytokines in the plasma, and epigenetic modiﬁcations such as micro
RNAs (miRs) expression contribute to the disease process. Vitamin
D supplementation or treatment, protect endothelial function and
may improve outcome in these patients. In the SOLID-trial, we
showed that treatment with a vitamin D receptor activator, (VDRA;
paricalcitol) is followed by a maintained endothelial function and
capillary blood ﬂow. Here, we report the effect of paricalcitol on
pro-inﬂammatory cytokines and miRs in plasma from patients in
the SOLID-trial.
Methods: 36 patients with eGFR of 15-59 mL/min/1.73 m2, calcium
< 2.6 mmol/L, and PTH level of 35-500 pg/mL were randomized
to 12 weeks treatment with placebo, 1 mg, or 2 mg paricalcitol.Kidney International Reports (2016) 1, S1–S22
